Fidelity Investments’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $310M | Buy |
4,303,188
+4,202,059
| +4,155% | +$239M | 0.02% | 678 |
|
|
2025
Q4 | $4.28M | Buy |
101,129
+61,162
| +153% | +$3.42M | ﹤0.01% | 2338 |
|
|
2025
Q3 | $2.27M | Buy |
39,967
+24,691
| +162% | +$817K | ﹤0.01% | 2495 |
|
|
2025
Q2 | $395K | Sell |
15,276
-322
| -2% | -$3.62K | ﹤0.01% | 3058 |
|
|
2025
Q1 | $159K | Sell |
15,598
-18,693
| -55% | -$244K | ﹤0.01% | 3342 |
|
|
2024
Q4 | $478K | Buy |
34,291
+8,514
| +33% | +$150K | ﹤0.01% | 2946 |
|
|
2024
Q3 | $503K | Buy |
25,777
+20,655
| +403% | +$394K | ﹤0.01% | 2855 |
|
|
2024
Q2 | $95.3K | Sell |
5,122
-3,241
| -39% | -$68.3K | ﹤0.01% | 3316 |
|
|
2024
Q1 | $117K | Sell |
8,363
-81
| -1% | -$848 | ﹤0.01% | 3214 |
|
|
2023
Q4 | $71.6K | Buy |
8,444
+3,335
| +65% | +$25.3K | ﹤0.01% | 3357 |
|
|
2023
Q3 | $45.6K | Sell |
5,109
-16,768
| -77% | -$161K | ﹤0.01% | 3408 |
|
|
2023
Q2 | $189K | Sell |
21,877
-6,885
| -24% | -$73.4K | ﹤0.01% | 2970 |
|
|
2023
Q1 | $303K | Buy |
28,762
+255
| +0.9% | +$7.71K | ﹤0.01% | 2849 |
|
|
2022
Q4 | $966K | Sell |
28,507
-2,256
| -7% | -$109K | ﹤0.01% | 2553 |
|
|
2022
Q3 | $1.48M | Buy |
30,763
+18,007
| +141% | +$1.07M | ﹤0.01% | 2512 |
|
|
2022
Q2 | $727K | Sell |
12,756
-3,902
| -23% | -$246K | ﹤0.01% | 2749 |
|
|
2022
Q1 | $1.35M | Sell |
16,658
-433,956
| -96% | -$64.2M | ﹤0.01% | 2714 |
|
|
2021
Q4 | $91.3M | Sell |
450,614
-483,236
| -52% | -$105M | 0.01% | 1136 |
|
|
2021
Q3 | $252M | Sell |
933,850
-122,703
| -12% | -$29.5M | 0.02% | 707 |
|
|
2021
Q2 | $272M | Sell |
1,056,553
-132,406
| -11% | -$36.6M | 0.02% | 690 |
|
|
2021
Q1 | $357M | Sell |
1,188,959
-74,353
| -6% | -$23.1M | 0.03% | 554 |
|
|
2020
Q4 | $322M | Sell |
1,263,312
-40,608
| -3% | -$10.5M | 0.03% | 550 |
|
|
2020
Q3 | $324M | Buy |
1,303,920
+25,172
| +2% | +$7.92M | 0.03% | 442 |
|
|
2020
Q2 | $444M | Sell |
1,278,748
-22,245
| -2% | -$6.94M | 0.05% | 349 |
|
|
2020
Q1 | $348M | Buy |
1,300,993
+305,125
| +31% | +$94.4M | 0.05% | 339 |
|
|
2019
Q4 | $322M | Buy |
995,868
+120,532
| +14% | +$35M | 0.04% | 460 |
|
|
2019
Q3 | $239M | Sell |
875,336
-368,214
| -30% | -$135M | 0.03% | 566 |
|
|
2019
Q2 | $664M | Sell |
1,243,550
-118,243
| -9% | -$59.3M | 0.08% | 253 |
|
|
2019
Q1 | $686M | Sell |
1,361,793
-368,975
| -21% | -$219M | 0.08% | 239 |
|
|
2018
Q4 | $853M | Buy |
1,730,768
+136,130
| +9% | +$82.2M | 0.12% | 152 |
|
|
2018
Q3 | $1.46B | Sell |
1,594,638
-119,089
| -7% | -$102M | 0.16% | 114 |
|
|
2018
Q2 | $1.26B | Buy |
1,713,727
+107,256
| +7% | +$124M | 0.14% | 136 |
|
|
2018
Q1 | $2.56B | Buy |
1,606,471
+856,940
| +114% | +$1.1B | 0.3% | 52 |
|
|
2017
Q4 | $671M | Buy |
749,531
+714,501
| +2,040% | +$423M | 0.08% | 270 |
|
|
2017
Q3 | $12.6M | Buy |
35,030
+2,116
| +6% | +$662K | ﹤0.01% | 1863 |
|
|
2017
Q2 | $9.65M | Sell |
32,914
-96,929
| -75% | -$28M | ﹤0.01% | 1955 |
|
|
2017
Q1 | $45.7M | Buy |
129,843
+38,689
| +42% | +$8.7M | 0.01% | 1344 |
|
|
2016
Q4 | $16.8M | Sell |
91,154
-50,920
| -36% | -$10.4M | ﹤0.01% | 1750 |
|
|
2016
Q3 | $36.6M | Buy |
142,074
+50,147
| +55% | +$12.9M | ﹤0.01% | 1433 |
|
|
2016
Q2 | $19.6M | Sell |
91,927
-11,640
| -11% | -$2.6M | ﹤0.01% | 1689 |
|
|
2016
Q1 | $21.4M | Sell |
103,567
-10,420
| -9% | -$2M | ﹤0.01% | 1631 |
|
|
2015
Q4 | $28.8M | Hold |
113,987
| – | – | ﹤0.01% | 1502 |
|
|
2015
Q3 | $18.7M | Hold |
113,987
| – | – | ﹤0.01% | 1680 |
|
|
2015
Q2 | $21.4M | Hold |
113,987
| – | – | ﹤0.01% | 1703 |
|
|
2015
Q1 | $18.8M | Hold |
113,987
| – | – | ﹤0.01% | 1748 |
|
|
2014
Q4 | $26.5M | Buy |
113,987
+73,793
| +184% | +$15.8M | ﹤0.01% | 1617 |
|
|
2014
Q3 | $7.28M | Buy |
+40,194
| New | +$7.69M | ﹤0.01% | 2109 |
|
|
2013
Q4 | – | Sell |
-7,953
| Closed | -$1.25M | – | 2664 |
|
|
2013
Q3 | $1.25M | Sell |
7,953
-7,187
| -47% | -$1.33M | ﹤0.01% | 2420 |
|
|
2013
Q2 | $2.62M | Buy |
+15,140
| New | +$2.32M | ﹤0.01% | 2274 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Fidelity Investments's NKTR Position: Q1 2026 in Review
Fidelity Investments increased its Nektar Therapeutics (NKTR) stake by 4,155% in Q1 2026, buying an estimated $239M and bringing the position to 4,303,188 shares worth $310M. The position accounts for 0.02% of the portfolio, ranked #678.
Fidelity Investments first reported a position in NKTR in Q2 2013 and has held it in 49 quarters since. The position peaked at $2.56B in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Fidelity Investments held 4,303,188 shares of Nektar Therapeutics worth $310M as of Q1 2026.
- Fidelity Investments bought 4,202,059 Nektar Therapeutics shares in Q1 2026, an estimated $239M.
- Nektar Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q1 2026, its #678 holding.
- Fidelity Investments first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Fidelity Investments's Nektar Therapeutics position peaked at $2.56B in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.